Pediatric-Type Follicular Lymphoma (PTFL) — a distinct and clinically unique follicular lymphoma variant recognized as a separate entity in the WHO classification of hematolymphoid tumors, predominantly affecting children and young adults (though occurring across the age spectrum with a median age at diagnosis in the second decade), characterized by its deceptive histologic appearance of large follicles with predominantly or exclusively centroblastic proliferation and a high Ki-67 proliferation index (frequently >30–90%, well above the typical follicular lymphoma range), contrasting sharply with its consistently indolent clinical behavior and excellent prognosis despite the aggressive histologic features that would predict high-grade disease in conventional follicular lymphoma grading schemas — arising without the BCL2 gene rearrangement t(14;18)(q32;q21) that defines the vast majority of conventional adult-type follicular lymphoma (making BCL2 negativity by immunohistochemistry a critical diagnostic feature separating PTFL from conventional FL and preventing misclassification as follicular lymphoma grade 3B with curative-intent chemotherapy implications), expressing CD20, CD79a, PAX5, CD10, BCL6, and CXCR4 (with IRF4/MUM1 variable and BCL2 typically negative or weakly expressed), frequently harboring IRF4 rearrangement as a recurrent molecular alteration in a subset (the IRF4-rearranged subgroup with distinctive features including CD10-positive IRF4-positive phenotype and sometimes challenging differential from large B-cell lymphoma with IRF4 rearrangement), presenting predominantly with localized peripheral lymph node involvement (particularly head and neck, inguinal, or axillary nodes) and rarely with advanced-stage disease or bone marrow involvement, treated primarily with surgical excision alone for localized disease (with excisional biopsy serving as both diagnostic and therapeutic), or with involved-field radiation therapy for residual disease, or with rituximab monotherapy for rare multifocal or relapsed disease — and requiring distinction from conventional adult follicular lymphoma grade 3B (treated with R-CHOP), IRF4-rearranged large B-cell lymphoma (treated more aggressively), and Burkitt lymphoma (the aggressive Ki-67-high differential that must be excluded histologically and molecularly) — demands care technology platforms designed to coordinate expert pediatric and young adult hematopathology review, molecular diagnostic testing (BCL2 FISH, IRF4 rearrangement, MYC FISH for Burkitt exclusion), surgical and procedural excision documentation, involved-field radiation therapy planning for selected cases, watchful waiting surveillance for non-excised residual disease, and long-term remission monitoring workflows across this rare and biologically distinctive benign-behaving lymphoma population.
PTFL technology platforms — whether supporting pathology diagnostic platforms (immunohistochemistry panels for CD20, CD79a, PAX5, CD10, BCL6, BCL2, Ki-67, IRF4/MUM1, MYC protein, CD3, CD5, CD23, cyclin D1 for mantle cell exclusion; FISH for BCL2, IRF4, MYC, BCL6 rearrangements; next-generation sequencing panels for TNFRSF14, MAP2K1, CREBBP, and IRF4 mutations; Burkitt lymphoma exclusion with MYC rearrangement FISH and Ki-67 assessment; detailed morphologic review for large follicle documentation and centroblast predominance; pattern analysis for follicular versus diffuse growth), surgical excision platforms (excisional biopsy coordination records; intraoperative pathology consultation documentation; surgical scheduling and operative records; post-excision pathology specimen processing; lymph node yield documentation), staging platforms (CT of neck/chest/abdomen/pelvis; bone marrow biopsy documentation for rare staged cases; Ann Arbor staging records; LDH and beta-2 microglobulin laboratory baseline records), involved-field radiation therapy platforms (radiation therapy planning documentation for incompletely excised or multi-site PTFL; low-dose involved-site radiation therapy volume delineation; dose-volume histogram analysis for organ-at-risk sparing in young patients; treatment delivery and verification records), rituximab monotherapy platforms for selected multifocal or relapsed cases (rituximab 375 mg/m² prescribing; infusion records and reaction documentation; response monitoring with CT surveillance after rituximab), and watchful waiting surveillance platforms (interval CT imaging schedule; clinical examination records; laboratory monitoring with LDH and CBC; patient education records for watchful waiting approach and transformation surveillance) — must maintain the availability and performance standards that PTFL's molecular diagnostic precision, surgical management, long-term surveillance, and transformation monitoring demand. This guide explains why PTFL tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the diagnostic complexity, predominantly localized disease management, long-term survivorship, and transformation surveillance requirements of modern PTFL care.
Why PTFL Tech Platforms Require Specialized Monitoring Attention
PTFL management is defined by the diagnostic precision required to distinguish it from conventional adult follicular lymphoma grade 3B (which would trigger R-CHOP chemotherapy), IRF4-rearranged large B-cell lymphoma (which requires more aggressive treatment), and Burkitt lymphoma (which demands emergency intensive chemotherapy) through comprehensive immunohistochemistry panel analysis and molecular FISH testing — a distinction with directly life-altering treatment implications where misclassification of PTFL as Burkitt lymphoma would expose a patient to unnecessary intensive chemotherapy with significant toxicity in a disease curable by simple excision, and where misclassification as conventional FL grade 3B would inappropriately trigger R-CHOP administration in a disease that does not require chemotherapy. Technology failures in the diagnostic, surgical, surveillance, and radiation platforms supporting PTFL management create disruptions calibrated to the clinical and oncologic consequences of management decisions in this diagnostically challenging entity.
Pathology diagnostic platforms are foundational for PTFL diagnosis and differential diagnosis. Comprehensive immunohistochemistry review documenting BCL2 negativity (the critical PTFL hallmark distinguishing it from conventional FL), CD10-positive BCL6-positive germinal center phenotype, high Ki-67 proliferation index with centroblast predominance, IRF4/MUM1 assessment (for IRF4-rearranged subgroup identification), and large follicle architecture — combined with FISH results for BCL2, IRF4, MYC, and BCL6 rearrangements to exclude conventional FL, IRF4-rearranged large B-cell lymphoma, and MYC-rearranged Burkitt lymphoma — require platforms that must support the multistep diagnostic algorithm where the integrated molecular and immunophenotypic profile drives the treatment intensity decision that distinguishes watchful waiting from chemotherapy. Monitor pathology diagnostic platforms at 1-minute intervals during business hours.
Surgical excision coordination platforms support the primary therapeutic intervention. Excisional biopsy scheduling and operative records for the complete lymph node excision that simultaneously establishes diagnosis and provides definitive treatment for most localized PTFL, intraoperative pathology consultation documentation, post-excision pathology specimen processing records, surgical pathology report integration with clinical staging, and surgical complication documentation — require platforms that must support the excisional biopsy-as-therapy workflow where complete excision of the involved lymph node is both the diagnostic procedure and the definitive treatment for most localized PTFL. Monitor surgical excision platforms at 1-minute intervals during business hours.
Long-term watchful waiting surveillance platforms manage the non-excised residual disease observation strategy. Interval CT imaging scheduling (surveillance CT at 3–6 month intervals for observed residual disease), clinical examination documentation at each visit, LDH and CBC laboratory monitoring, symptom assessment records (B symptoms, progressive lymphadenopathy), patient education documentation for the watchful waiting approach (educating patients about the excellent prognosis, the potential for spontaneous remission, and the transformation risk surveillance rationale), and transformation surveillance records — require platforms that must coordinate the longitudinal observation strategy for patients with incompletely excised or multi-site PTFL who are managed without additional therapy, where transformation to aggressive lymphoma, though rare, requires early detection. Monitor watchful waiting surveillance platforms at 1-minute intervals during business hours.
IRF4-rearranged subgroup molecular tracking requires specialized platform support. IRF4 rearrangement FISH documentation (identification of the IRF4-rearranged PTFL subgroup), IRF4/MUM1 immunohistochemistry correlation (strong IRF4 expression associated with IRF4 rearrangement), TNFRSF14 and MAP2K1 mutation testing records, next-generation sequencing panel results for CREBBP and other common PTFL mutations, and IRF4-rearranged subgroup-specific treatment consideration records (where the distinction from IRF4-rearranged large B-cell lymphoma, which may require more aggressive treatment, must be clearly documented) — require platforms that must integrate the molecular profile that refines PTFL subgroup classification and informs the rare cases where the IRF4-rearranged phenotype creates clinical uncertainty about the appropriate treatment approach. Monitor molecular diagnostic platforms at 1-minute intervals during business hours.
Rituximab monotherapy platforms support selected multifocal or relapsed PTFL. Rituximab 375 mg/m² prescribing and infusion records (for rare multifocal PTFL not amenable to complete excision or for relapsed disease), premedication records, infusion reaction documentation, CT surveillance imaging after rituximab for response assessment, response duration monitoring, and re-treatment records for rituximab-responsive relapsed disease — require platforms that must coordinate the limited systemic therapy use in a disease where even relapsed or multifocal PTFL typically follows an indolent course and rituximab monotherapy without chemotherapy is frequently sufficient. Monitor rituximab administration platforms at 1-minute intervals during infusion sessions.
What to Monitor on a PTFL Tech Platform
Pathology Diagnostic Decision Support and Molecular Testing
Monitor comprehensive immunohistochemistry panel records (BCL2 staining results documenting negativity critical for PTFL diagnosis; CD10, BCL6, CD20, CD79a, PAX5, IRF4/MUM1, Ki-67, MYC protein, CD3, CD5, CD23, cyclin D1 results; large follicle architecture documentation; centroblast predominance morphology records), FISH records (BCL2 rearrangement with IGH — expected negative in PTFL; IRF4 rearrangement status; MYC rearrangement for Burkitt exclusion; BCL6 rearrangement), next-generation sequencing records (TNFRSF14, MAP2K1, CREBBP, IRF4 mutation analysis), Burkitt lymphoma exclusion documentation (MYC-negative FISH, Ki-67 morphology review, morphologic assessment distinguishing centroblast-predominant follicular growth from diffuse medium-cell Burkitt morphology), multidisciplinary tumor board review records, and expert hematopathology consultation records at 1-minute intervals during business hours. Alert immediately — pathology diagnostic platform failures disrupt the integrated immunohistochemistry and molecular workup where BCL2 negativity by FISH and immunohistochemistry, IRF4 rearrangement status, and MYC exclusion together establish PTFL diagnosis and prevent life-altering misclassification as Burkitt lymphoma or conventional FL grade 3B.
Surgical Excision Coordination
Monitor excisional biopsy scheduling records (operative scheduling, surgeon documentation, anesthesia records), pre-operative workup records (pre-operative CBC, coagulation studies, imaging for surgical planning), intraoperative pathology consultation records (frozen section consultation documentation, gross specimen assessment), surgical operative records (node excision documentation, lymph node yield, anatomic site), post-operative pathology specimen processing records (formalin fixation, block submission, staining protocol), surgical pathology report records, and post-operative complication documentation at 1-minute intervals during business hours. Alert immediately — surgical excision platform failures disrupt the coordination of excisional biopsy scheduling, intraoperative pathology consultation, and specimen processing records for the primary therapeutic procedure in localized PTFL.
Watchful Waiting Surveillance and Transformation Monitoring
Monitor interval CT imaging scheduling records (CT neck/chest/abdomen/pelvis at 3–6 month intervals for observed residual disease; transition to annual surveillance after stability documentation), clinical examination records at each surveillance visit, LDH laboratory results at surveillance visits, complete blood count results, B symptom assessment documentation (fever, night sweats, weight loss as transformation risk signals), lymph node size measurement records and progression documentation, patient education records documenting watchful waiting approach education and transformation warning signs, and spontaneous remission documentation records at 1-minute intervals during business hours. Alert immediately — watchful waiting surveillance platform failures disrupt the long-term interval imaging and clinical monitoring that detects the rare but critical transformation to aggressive lymphoma in PTFL patients managed without excision or radiation.
Staging and Disease Burden Assessment
Monitor CT staging records (CT of neck/chest/abdomen/pelvis with contrast for anatomic staging), Ann Arbor staging documentation (predominantly stage I–II at PTFL diagnosis), bone marrow biopsy records (for rare staged cases with bulky or multi-site disease), LDH baseline and surveillance results, beta-2 microglobulin baseline records, complete blood count at staging and surveillance visits, and PET-CT records when performed for staging or response assessment at 1-minute intervals during business hours. Alert immediately — staging platform failures delay the localized versus advanced-stage determination that distinguishes the vast majority of PTFL patients (stage I–II, excision only) from the rare advanced-stage presentation warranting additional workup.
Involved-Field Radiation Therapy Planning and Delivery
Monitor involved-site radiation therapy referral records (for incompletely excised or multi-site PTFL not amenable to complete excision), radiation therapy simulation and planning records (CT simulation, GTV/CTV/PTV delineation for involved lymph node regions; low-dose approach with 24 Gy in 2 Gy fractions or 4 Gy in 2 Gy fractions for selected cases), dose-volume histogram analysis records (organ-at-risk constraints for young patients: parotid gland sparing for head and neck sites; thyroid dose constraint; gonadal shielding for inguinal sites; cardiac and pulmonary sparing for mediastinal sites), treatment delivery records with daily imaging verification, acute toxicity documentation, and late-effects monitoring planning records at 1-minute intervals during active radiation treatment. Alert immediately — radiation therapy planning platform failures disrupt the involved-site volume delineation and dose-volume histogram optimization required for young patients where minimizing long-term radiation toxicity to adjacent organs is essential given the expected decades-long survival.
IRF4-Rearranged Subgroup Tracking
Monitor IRF4 rearrangement FISH records and interpretation documentation, IRF4/MUM1 immunohistochemistry correlation records (strong expression raising IRF4 rearrangement suspicion), differential diagnosis records distinguishing IRF4-rearranged PTFL from IRF4-rearranged large B-cell lymphoma (where PTFL has follicular architecture and indolent behavior versus DLBCL-type aggressive behavior), molecular panel mutation results for IRF4-rearranged subgroup (TNFRSF14, MAP2K1), and treatment documentation for IRF4-rearranged PTFL cases where subgroup classification drives management decisions at 1-minute intervals during business hours. Alert immediately — IRF4 subgroup molecular platform failures disrupt the classification records that distinguish the IRF4-rearranged PTFL subgroup (indolent, excision adequate) from IRF4-rearranged large B-cell lymphoma (aggressive, requiring intensive treatment) in diagnostic uncertainty cases.
Rituximab Administration for Multifocal or Relapsed PTFL
Monitor rituximab prescribing records (375 mg/m² dose calculation with body surface area verification; pharmacy verification), premedication records (acetaminophen, diphenhydramine, methylprednisolone), infusion administration records including infusion rate escalation documentation, infusion reaction documentation and management records, post-rituximab CT response assessment scheduling and records, response duration documentation, and re-treatment consideration records for rituximab-sensitive relapsed disease at 1-minute intervals during infusion sessions. Alert immediately — rituximab administration platform failures during infusion disrupt the safety monitoring and pharmacy verification required for rituximab monotherapy in the selected PTFL cases where systemic therapy is indicated.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. PTFL programs coordinate across pediatric and adult hematology-oncology, pediatric and adult hematopathology (with frequent expert consultation given the diagnostic rarity), surgery (for excisional biopsy), radiation oncology (for involved-site treatment in selected cases), and pharmacy (for rituximab in multifocal or relapsed cases) — authentication failures simultaneously block every member of the multidisciplinary team managing a patient whose diagnostic precision, surgical planning, watchful waiting coordination, and long-term surveillance all require coordinated platform access.
SSL Certificates
Monitor SSL certificate expiry across all pathology diagnostic platforms, surgical coordination systems, surveillance scheduling tools, radiation therapy planning platforms, and watchful waiting monitoring applications. Certificate errors disrupt the integrated diagnostic, surgical coordination, surveillance, radiation planning, and long-term monitoring workflows of PTFL management.
HIPAA and Oncology Data Privacy Considerations
PTFL technology platforms handle sensitive PHI including comprehensive lymphoma pathology reports with molecular diagnostic results (BCL2 FISH negativity, IRF4 rearrangement status, MYC FISH, next-generation sequencing mutation panels), surgical operative records for excisional biopsy, longitudinal watchful waiting surveillance CT imaging records, involved-site radiation therapy planning records with dose-volume histograms, rituximab administration records for multifocal or relapsed cases, and long-term transformation surveillance records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing longitudinal surveillance records in pediatric and young adult PTFL patients — where the watchful waiting approach generates years to decades of surveillance CT imaging, laboratory monitoring, and clinical examination records extending from adolescence or young adulthood through middle age — privacy and access controls must reflect the multi-decade duration of PHI retention and the particular sensitivity of oncology records created in childhood and young adulthood where the patient's evolving legal status (minor to adult) creates additional access control considerations. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for programs managing PTFL's intersection of pediatric lymphoma diagnostics, surgical records, long-term surveillance, and transformation monitoring PHI.
Alerting Strategy for PTFL Tech Platforms
Immediate alerting during active radiation treatment: Involved-site radiation therapy delivery platforms, daily imaging verification, and acute toxicity documentation cannot fail during active treatment in young patients where treatment accuracy is essential for organ-at-risk sparing and long-term toxicity prevention.
Immediate alerting during rituximab infusion: Rituximab administration platforms, infusion reaction monitoring, and pharmacy verification records during active infusion sessions.
Immediate business-hours alert: Pathology diagnostic platforms, molecular testing coordination, surgical excision scheduling, IRF4 subgroup tracking, and watchful waiting surveillance. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Long-term surveillance scheduling, transformation risk documentation, and lymphoma registry platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms PTFL platform availability from the geographies where pediatric hematology-oncology programs, expert hematopathology consultation services, and radiation oncology facilities serving young patients concentrate — academic children's hospitals and young adult oncology programs where the diagnostic expertise and age-appropriate care infrastructure that PTFL demands are available.
Status Page for PTFL Care Team Communication
A real-time status page gives hematology-oncologists managing PTFL in children and young adults, hematopathologists reviewing BCL2-negative high-Ki-67 follicular lymphoma cases for differential diagnosis, surgeons planning excisional biopsy as primary therapy, radiation oncologists delineating involved-site volumes for low-dose treatment in young patients, and pharmacists verifying rituximab infusions for multifocal disease immediate platform visibility without requiring inbound IT support contact. During a pathology platform outage when a multidisciplinary team reviews a 14-year-old's cervical lymph node biopsy showing large follicles with >80% Ki-67-positive centroblasts, BCL2-negative immunohistochemistry, and pending BCL2 FISH to exclude conventional FL grade 3B and pending MYC FISH to exclude Burkitt lymphoma — where the treatment decision pending molecular results ranges from observation after excision (PTFL) to emergency CODOX-M/IVAC (Burkitt) — a status page enables immediate contingency protocol activation ensuring that manual molecular result retrieval and emergency pathology consultation workflows can proceed without delay.
Include the status page URL in lymphoma program downtime procedures, pediatric hematology-oncology emergency protocols, excisional biopsy emergency pathology consultation workflows, involved-site radiation therapy emergency treatment procedures, and transformation emergency management contingency procedures.
Vigilmon Setup for PTFL Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Pathology diagnostic decision support (IHC, FISH, NGS) | 1 min | Slack + PagerDuty (business hours) | | Surgical excision coordination | 1 min | Slack + PagerDuty (business hours) | | Staging and disease burden assessment | 1 min | Slack + PagerDuty (business hours) | | IRF4-rearranged subgroup molecular tracking | 1 min | Slack + PagerDuty (business hours) | | Watchful waiting surveillance scheduling | 1 min | Slack + PagerDuty (business hours) | | Involved-field radiation therapy planning and delivery | 1 min | Slack + PagerDuty (treatment hours) | | Rituximab monotherapy administration | 1 min | Slack + PagerDuty (infusion hours) | | Long-term transformation surveillance | 2 min | Slack (business hours) | | Patient/family communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure pathology diagnostic platforms (immunohistochemistry, FISH, NGS) with immediate business-hours alerting
- Add surgical excision coordination platforms with immediate business-hours alerting
- Configure staging and disease burden assessment platforms with immediate business-hours alerting
- Add IRF4-rearranged subgroup molecular tracking platforms with immediate business-hours alerting
- Configure watchful waiting surveillance scheduling with immediate business-hours alerting
- Add involved-site radiation therapy planning and delivery platforms with immediate alerting during active treatment
- Configure rituximab monotherapy administration platforms with immediate alerting during infusion sessions
- Add long-term transformation surveillance platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all pathology, surgical coordination, surveillance, radiation, and watchful waiting domains
- Add the status page URL to lymphoma program downtime procedures, emergency pathology consultation protocols, surgical excision emergency workflows, and radiation therapy emergency treatment procedures
Conclusion
PTFL technology platforms are embedded in clinical decisions where pathology diagnostic platform availability when a pediatric hematology-oncologist receives the pathology report on a 16-year-old's inguinal lymph node excision showing large follicles with 90% Ki-67-positive centroblasts — where the hematopathologist reviewing the immunohistochemistry showing CD20-positive, BCL6-positive, CD10-positive, BCL2-negative B-cells with a high-grade morphologic appearance that would suggest aggressive lymphoma without the molecular context, reporting the BCL2 FISH as negative (excluding conventional FL with t(14;18)) and the MYC FISH as negative (excluding Burkitt lymphoma), and documenting the IRF4 rearrangement status and TNFRSF14 mutation analysis that establish the PTFL molecular profile — determines whether the oncologist's treatment plan is watchful waiting after successful excision (PTFL confirmed: no further treatment needed, excellent prognosis) or emergency CODOX-M/IVAC (if molecular results cannot be accessed when Burkitt lymphoma remains on the differential); where watchful waiting surveillance platform availability when a 21-year-old with known PTFL managed with excision presents for their 6-month surveillance visit — where the oncologist reviewing the CT showing a new 2.5-cm inguinal lymph node on the contralateral side from the original excision site, considering whether this represents PTFL recurrence warranting repeat excision or rituximab monotherapy versus rare PTFL transformation to aggressive lymphoma requiring biopsy and re-staging — cannot be delayed by platform unavailability when the surveillance imaging interpretation and prior pathology comparison require simultaneous access to historical CT measurements, original pathology immunohistochemistry, and current imaging; and where involved-site radiation therapy planning platform availability when a 17-year-old with residual PTFL not amenable to complete excision requires radiation therapy planning — where the radiation oncologist delineating the involved cervical lymph node target volume on CT simulation images, optimizing the dose-volume histogram for parotid gland sparing to minimize xerostomia risk in a teenager expected to live 60+ more years, and selecting between IMRT and proton therapy for optimal normal tissue protection — determines whether the radiation planning optimization proceeds with full imaging and dosimetry access or with critical gaps from platform unavailability. A pathology diagnostic platform that fails when BCL2 FISH and MYC FISH results are needed to distinguish PTFL from Burkitt lymphoma and prevent unnecessary intensive chemotherapy, a watchful waiting surveillance system inaccessible when new adenopathy requires urgent comparison with prior imaging to assess transformation risk, a radiation therapy planning platform unavailable when young patient dose-volume histogram optimization requires complete dosimetry data — these are not IT incidents. They are clinical disruptions in the management of a rare deceptively aggressive-appearing but behaviorally indolent lymphoma where diagnostic precision preventing chemotherapy overtreatment, long-term surveillance enabling transformation detection, and radiation therapy optimization protecting young patients' decades-long future organ function all require that pathology, staging, surgical coordination, surveillance, molecular subgrouping, radiation planning, and watchful waiting monitoring platforms are reliably available at every critical decision point.
Uptime monitoring gives PTFL tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pediatric hematology-oncology programs, expert hematopathology consultation services, radiation oncology centers serving young patients, and compliance auditors that platform operational reliability matches the rare pediatric lymphoma diagnostic precision demands, excision-as-therapy coordination requirements, long-term watchful waiting surveillance obligations, and radiation therapy optimization responsibilities of modern PTFL care.
Start monitoring your Pediatric-Type Follicular Lymphoma care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #PTFL #pediatrictypefollicularlymphoma #follicularlymphoma #BCL2negative #IRF4 #Burkittexclusion #watchfulwaiting #excisionalbiopsy #involvedisite #radiationtherapy #rituximab #transformation #TNFRSF14 #MAP2K1 #pediatriclymphoma #youngadultoncology #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre